Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 7/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624298 | 0.84 | MCHR1 (0.45) | MCHR1BCHE | |
| SCHEMBL3475699 | 0.82 | MCHR1 (0.50) | MCHR1CYP1A2CYP2D6CYP3A4HTR6 | |
| SCHEMBL16624342 | 0.78 | CHRM2 (0.59) | MCHR1CYP1A2CYP2D6CYP3A4HTR6 | |
| SCHEMBL8803935 | 0.78 | CYP1A2 (0.73) | CYP1A2CYP2D6HTR6HRH1 | |
| SCHEMBL25634076 | 0.75 | MCHR1 (0.50) | MCHR1CYP1A2CYP2D6HTR6HRH1 | |
| SCHEMBL21588441 | 0.75 | ESR2 (0.45) | MCHR1 | |
| SCHEMBL16610030 | 0.75 | MCHR1 (0.51) | MCHR1CYP3A4 | |
| SCHEMBL13233206 | 0.74 | HTR6 (0.53) | CYP1A2CYP2D6HTR6HRH1BCHE | |
| Hydrochloric Acid SCHEMBL17940522 | 0.74 | KDM4E (0.51) | MCHR1CYP3A4 | |
| SCHEMBL11424347 | 0.73 | MCHR1 (1.00) | MCHR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | MCHR1 3517/4885CYP1A2 1560/4885CYP2D6 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.